Ref. Ares(2018)3179967 - 15/06/2018
Ref. Ares(2019)631504 - 04/02/2019
Ms Roxane Feller
168 Avenue de Tervueren
Box 8, 5th floor
B- 1150 Brussels E-mail:
Dear Ms Feller,
Thank you for your letter of 12 April to Vice-President Timmermans, in which you
expressed concerns regarding the Commission’s upcoming initiative on Supplementary
(‘SPCs’). I am pleased to reply to you on behalf of the
Please rest reassured that the Commission is fully aware of the importance of an effective
IPR protection for the pharmaceutical industry (including the veterinary sector). This is
demonstrated by the quality of the related legislation currently in force and by the fact
that the Commission is routinely negotiating with third countries in the perspective of
strengthening their IPR legislative framework.
It should also be noted that the Commission does not intend to affect in any way the core
objectives of the SPC regime, namely to provide SPC holders with the exclusive right to
place their products on the EU market during the SPC term.
For your information, all of the documents you mentioned (including two studies and a
report on our public consultation) are in the process of being finalised and will be
published shortly on the Commission website.
Electronically signed on 14/06/2018 18:01 (UTC+02) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563
Electronically signed on 04/02/2019 15:18 (UTC+01) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563